- Home
- NITO vs VIVS Comparison
NITO vs VIVS Comparison
Compare NITO & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NITO
- VIVS
- Stock Information
- Founded
- NITO 2009
- VIVS 2007
- Country
- NITO Israel
- VIVS United States
- Employees
- NITO N/A
- VIVS N/A
- Industry
- NITO
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NITO
- VIVS Health Care
- Exchange
- NITO NYSE
- VIVS Nasdaq
- Market Cap
- NITO 4.2M
- VIVS 3.6M
- IPO Year
- NITO N/A
- VIVS N/A
- Fundamental
- Price
- NITO $0.30
- VIVS $1.84
- Analyst Decision
- NITO
- VIVS
- Analyst Count
- NITO 0
- VIVS 0
- Target Price
- NITO N/A
- VIVS N/A
- AVG Volume (30 Days)
- NITO 5.6M
- VIVS 71.5K
- Earning Date
- NITO 05-15-2025
- VIVS 06-13-2025
- Dividend Yield
- NITO N/A
- VIVS N/A
- EPS Growth
- NITO N/A
- VIVS N/A
- EPS
- NITO N/A
- VIVS N/A
- Revenue
- NITO $232,000.00
- VIVS $144,000.00
- Revenue This Year
- NITO N/A
- VIVS $59.08
- Revenue Next Year
- NITO N/A
- VIVS $18.24
- P/E Ratio
- NITO N/A
- VIVS N/A
- Revenue Growth
- NITO 24.74
- VIVS N/A
- 52 Week Low
- NITO $0.16
- VIVS $1.56
- 52 Week High
- NITO $3.49
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- NITO 49.96
- VIVS N/A
- Support Level
- NITO $0.25
- VIVS N/A
- Resistance Level
- NITO $0.30
- VIVS N/A
- Average True Range (ATR)
- NITO 0.03
- VIVS 0.00
- MACD
- NITO -0.00
- VIVS 0.00
- Stochastic Oscillator
- NITO 67.66
- VIVS 0.00
About NITO N2OFF INC
N2OFF Inc is a pioneering agri-food tech company dedicated to developing sustainable solutions for the plant-based food industry. Operating through two subsidiaries, it delivers integrated solutions for enhanced safety, quality, and sustainability from field to fork. The Company has two reportable segments: Pathogen prevention and prolong shelf life, and the N2O emissions Global warming solutions.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.